In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO ...

State agents say a Summerville shop operator kept running it after his license was revoked, used a false name, and threatened ...

As CTV grows, TaaS offers a seamless, cost-effective solution to OTT chaos, making premium entertainment accessible across ...

Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 ...

THE son of Brazil legend Rivaldo has put pen to paper at Thai minnows True Bangkok United. Rivaldo Vítor Mosca Ferreira ...

Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...

Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...

Federal prosecutors seek a long prison sentence for R.J. May, the SC ex-state lawmaker guilty of distributing child porn on ...

ContrastConnect has rolled out its physician-led virtual contrast supervision platform, which is designed to address the ...